News

Editor's Top Picks

REX American Resources Corporation 2026 Q3 – Results – Earnings Call Presentation (NYSE:REX) 2025-12-05

This article was written byFollowSeeking Alpha's transcripts team is responsible for the development of all of our transcript-related projects. We

News

Your one-stop resource for personal news and tips.

Join our newsletter to get the latest news directly to your inbox.

More form News

United Therapeutics: Fundamental And Technical Analyses Justify A Buy Decision (UTHR)

Investment Thesis United Therapeutics Corporation (NASDAQ:UTHR) has been in a long-term uptrend since 2019, making

Israelis queue to buy guns in aftermath of Hamas attacks

In a suburb of the Israeli city of Kefar Sava, gunshots rang out on a

Comus Investment Q3 2023 Letter

*April 1st – Dec 31st, 2016 The compounded performance figures represent all realized and unrealized

Ten years of China’s Belt and Road: what has $1tn achieved?

“When you give roses to others, their fragrance lingers on your hand,” Xi Jinping told

ClearBridge Global Infrastructure Value Strategy Q3 2023 Portfolio Manager Commentary

By Charles Hamieh, Shane Hurst, Nick Langley, & Simon Ong Utilities Fundamentals Intact as Market

Executive at WPP-owned agency detained over bribery claims

Unlock the Editor’s Digest for freeRoula Khalaf, Editor of the FT, selects her favourite stories

Equifax: Guidance Revised But Uncertainty Remains (NYSE:EFX)

Overview My recommendation for Equifax (NYSE:EFX) is a hold rating as there is a lot

US signals intention to engage with Niger junta

Unlock the Editor’s Digest for freeRoula Khalaf, Editor of the FT, selects her favourite stories

Enterprise Products Partners: A Strong Second Half Expected, FCF Gains Ahead (NYSE:EPD)

High-dividend stocks have been battered on a relative basis in 2023 as rising interest rates

Big companies defy expectations to become even bigger

Stay informed with free updatesSimply sign up to the Companies myFT Digest -- delivered directly

Bristol-Myers Squibb Acquisition Of Mirati Makes Sense (NYSE:BMY)

Bristol-Myers Squibb (NYSE:BMY) is one of the largest pharmaceutical companies in the world with a

Ark finds silver lining in massive ETF losses: years of tax benefits

Stay informed with free updatesSimply sign up to the Exchange traded funds myFT Digest --

AngloGold Ashanti: Good Growth Prospect (NYSE:AU)

Part I: Introduction Johannesburg-based AngloGold Ashanti Limited (NYSE:AU) released its H1 2023 results ending June

Diplomacy faces four tough challenges on Israel and Gaza

Unlock the Editor’s Digest for freeRoula Khalaf, Editor of the FT, selects her favourite stories

Beam: Opportunity Based On SCD Data Readout In 2024 (NASDAQ:BEAM)

Beam Therapeutics (NASDAQ:BEAM) has made significant progress in being able to advance its pipeline forward.